NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.    The investigation concerns whether Mereo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On July ...

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Simulations Plus, Inc. (“Simulations Plus” or the “Company”) (NASDAQ: SLP).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Simulations Plus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class ...

公司财务表现 - 洛克希德马丁2025年第二季度财报显示盈利大幅下滑 包括16亿美元的项目损失 [3] - 航空机密项目因设计、集成和测试挑战导致9.5亿美元损失 公司需调整流程和测试方法 [3] - 加拿大海上直升机项目因增加任务能力、延长舰队寿命等因素导致5.7亿美元损失 [3] - 土耳其通用直升机项目因当前状态计提9500万美元费用 [3] 股价影响 - 财报发布后公司股价单日下跌49.84美元(10.8%) 收盘报410.69美元 [4] 法律调查 - Pomerantz律师事务所正在调查公司是否存在证券欺诈或其他非法商业行为 [1] - 调查涉及公司及其部分高管可能违反证券法的行为 [1] 合同谈判 - 公司正与客户就部分合同条款的重构进行持续讨论 [3]

公司调查事件 - Telix Pharmaceuticals Limited因涉嫌证券欺诈或其他非法商业行为正被Pomerantz LLP调查 [1] - 调查涉及公司及其部分高管或董事是否违反证券法规 [1] 股价影响 - Telix于2025年7月22日披露收到美国证券交易委员会 subpoena 要求提供前列腺癌治疗候选药物相关披露文件 [3] - 消息公布后公司ADR价格下跌1.70美元(跌幅10.44%)至14.58美元/ADR [3] 法律背景 - Pomerantz LLP在证券集体诉讼领域具有领先地位 曾为投资者追回数百万美元赔偿 [4] - 该律所在纽约 芝加哥 洛杉矶 伦敦和巴黎设有办公室 专长于公司证券和反垄断集体诉讼 [4]

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Encompass Health Corporation (“Encompass” or the “Company”) (NYSE: EHC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Encompass and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On ...

诉讼事件 - 针对Flywire公司及其部分高管提起集体诉讼 指控其在2024年2月28日至2025年2月25日期间违反联邦证券法 [1] - 诉讼依据为《1934年证券交易法》第10(b)条和第20(a)条以及据此制定的10b-5规则 [1] - 投资者需在2025年9月23日前申请成为首席原告 [2] 公司业务 - 公司为支付赋能和软件企业 运营覆盖美国及国际市场 其支付平台和垂直行业软件促进跨行业客户间支付 [4] - 教育领域是最大垂直市场 业务表现高度依赖国际学生入学率和地区偏好 重点关注美洲(美加)和亚太(澳大利亚)市场 [5] - 采用非GAAP财务指标评估业绩 包括扣除辅助服务收入(RLAS)和汇率中性RLAS [5] 经营风险 - 加拿大政府2024年1月起实施国际学生许可上限 澳大利亚2023年末收紧学生签证规则 均导致支付流量减少并冲击业务 [6] - 管理层持续淡化签证政策负面影响 2024年11月仍宣称将保持"40法则"公司地位 预计2025年汇率中性RLAS增长低20%区间 [7] 财务表现 - 2025年2月25日公布的2024年Q4财报显示 每股亏损0.12美元(低于预期0.12美元) 收入1.176亿美元(低于预期125万美元) [9] - 2025年RLAS增长指引大幅下调至10-14%(原预期低20%区间) 并宣布裁员10% [9][10] - 电话会议披露教育业务恶化 四大主要市场学生签证签发量两位数下滑 预计加澳市场收入将同比下降超30% [11] 市场反应 - 财报发布后分析师密集下调评级和目标价 指出2025年收入指引与先前表述严重不符 [12] - 公告次日公司股价单日暴跌37.36%(6.59美元) 收报11.05美元 [13]

NEW YORK, July 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO).Shareholders who purchased shares of ANRO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/alto-neuroscience-inc-loss-submission-form/?id=158134&from=4CLASS PERIOD: This laws ...

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Investors have until August 25, 2025, to ask th ...